NCT02211859View on ClinicalTrials.gov

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2007

Conditions
Neoplasms
Interventions
DRUG

BI 2536

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02211859 - Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit | Biotech Hunter | Biotech Hunter